Repositioning synthetic glucocorticoids in psychiatric disease associated with neural autoantibodies : a narrative review
© 2022. The Author(s)..
Synthetic glucocorticoids (sGCs) are a well-investigated and standard drug therapy for disorders associated with CNS inflammation. Less is known about treating psychiatric disorders associated with neural autoantibodies. Our aim is to elucidate the repositioning of sGCs in psychiatric diseases that co-exist with neural autoantibodies. We used PubMed to identify articles for this narrative review. To our knowledge, no randomized, placebo-controlled trials have yet been conducted on applying sGC to treat neural autoantibody-associated psychiatric disorders. We describe initial results of cohort studies and single cases or case series often associated with autoantibodies against membrane-surface antigens demonstrating a largely beneficial response to sGCs either as monotherapy or polytherapy together with other immunosuppressive agents. However, sGCs may be less efficient in patients with psychiatric diseases associated with autoantibodies directed against intracellular antigens. These results reveal potential benefits of the novel usage of sGCs for the indication of neural autoantibody-associated psychiatric disease. Further large-scale randomized, placebo-controlled trials are needed to discover whether sGCs are safe, well tolerated, and beneficial in subgroups of neural autoantibody-associated psychiatric diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:130 |
|---|---|
| Enthalten in: |
Journal of neural transmission (Vienna, Austria : 1996) - 130(2023), 8 vom: 28. Aug., Seite 1029-1038 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hansen, Niels [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Autoantibodies |
|---|
| Anmerkungen: |
Date Completed 31.07.2023 Date Revised 01.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00702-022-02578-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350879699 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350879699 | ||
| 003 | DE-627 | ||
| 005 | 20231226050004.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00702-022-02578-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1169.xml |
| 035 | |a (DE-627)NLM350879699 | ||
| 035 | |a (NLM)36576564 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hansen, Niels |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Repositioning synthetic glucocorticoids in psychiatric disease associated with neural autoantibodies |b a narrative review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.07.2023 | ||
| 500 | |a Date Revised 01.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a Synthetic glucocorticoids (sGCs) are a well-investigated and standard drug therapy for disorders associated with CNS inflammation. Less is known about treating psychiatric disorders associated with neural autoantibodies. Our aim is to elucidate the repositioning of sGCs in psychiatric diseases that co-exist with neural autoantibodies. We used PubMed to identify articles for this narrative review. To our knowledge, no randomized, placebo-controlled trials have yet been conducted on applying sGC to treat neural autoantibody-associated psychiatric disorders. We describe initial results of cohort studies and single cases or case series often associated with autoantibodies against membrane-surface antigens demonstrating a largely beneficial response to sGCs either as monotherapy or polytherapy together with other immunosuppressive agents. However, sGCs may be less efficient in patients with psychiatric diseases associated with autoantibodies directed against intracellular antigens. These results reveal potential benefits of the novel usage of sGCs for the indication of neural autoantibody-associated psychiatric disease. Further large-scale randomized, placebo-controlled trials are needed to discover whether sGCs are safe, well tolerated, and beneficial in subgroups of neural autoantibody-associated psychiatric diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Autoantibody | |
| 650 | 4 | |a Drug repositioning | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Psychiatry | |
| 650 | 4 | |a Synthetic glucocorticoids | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 700 | 1 | |a Neyazi, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a Lüdecke, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Hasan, Alkomiet |e verfasserin |4 aut | |
| 700 | 1 | |a Wiltfang, Jens |e verfasserin |4 aut | |
| 700 | 1 | |a Malchow, Berend |e verfasserin |4 aut | |
| 700 | 0 | |a CAP (Cerebrospinal Fluid Analysis in Psychiatry) Consortium |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of neural transmission (Vienna, Austria : 1996) |d 1998 |g 130(2023), 8 vom: 28. Aug., Seite 1029-1038 |w (DE-627)NLM087117487 |x 1435-1463 |7 nnns |
| 773 | 1 | 8 | |g volume:130 |g year:2023 |g number:8 |g day:28 |g month:08 |g pages:1029-1038 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00702-022-02578-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 130 |j 2023 |e 8 |b 28 |c 08 |h 1029-1038 | ||